- COVID-19 Provider Relief Fund: HRSA continues to recover remaining payments due from providers : report to congressional committees1
- COVID-19: USAID plans to share lessons learned from efforts to meet global vaccination goal : report to congressional addressees1
- Certain Medicare beneficiaries, such as urban and Hispanic beneficiaries, were more likely than others to use telehealth during the first year of the COVID-19 pandemic1
- Challenges with vaccination data hinder state and local immunization program efforts to combat COVID-191
- Cleaner health care: hospital emissions mitigation1
- Compliance policy regarding blood and blood component donation suitability, donor eligibility and source plasma quarantine hold requirements: guidance for industry1
- Connecticut Medicaid Fraud Control Unit: 2021 inspection1
- Connecticut implemented our prior audit recommendations and generally complied with federal and state requirements for reporting and monitoring critical incidents1
- Considerations for the conduct of clinical trials of medical products during major disruptions due to disasters and public health emergencies: guidance for industry, investigators, and institutional review boards1
- Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry1
- Cybersecurity in medical devices: quality system considerations and content of premarket submissions : guidance for industry and Food and Drug Administration staff1
- DSCSA standards for the interoperable exchange of information for tracing of certain human, finished, prescription drugs: guidance for industry1
- Defense health care: DOD assessment needed to ensure TRICARE behavioral health coverage goals are being met : report to congressional committees1
- Development and licensure of vaccines to prevent COVID-19: guidance for industry1
- Development of monoclonal antibody products targeting SARS-CoV-2 for emergency use authorization: guidance for industry1
- Digital health technologies for remote data acquisition in clinical investigations: guidance for industry, investigators, and other stakeholders1
- Direct-to-consumer prescription drug advertisements: presentation of the major statement in a clear, conspicuous, and neutral manner in advertisements in television and radio format final rule : questions and answers : guidance for industry1
- During the initial COVID-19 response, HHS personnel who interacted with potentially infected passengers had limited protections1
- Early challenges highlight areas for improvement in COVID-19 vaccination programs1
- Enforcement policy for certain supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) submissions: guidance for industry and Food and Drug Administration staff1